

W, E, C, k E, W, k
k
k



(A joint stock limited liability company incorporated in the

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

		For the six months ended June 30,	
		2020	2019
		(RMB'000)	(USD'000)
		(Unaudited)	(Unaudited)
Revenue		465,150	378,910
Cost of revenue		39,404	52,661
Revenue from operations		(10,503)	(7,120)
Operating expenses		28,901	45,541
Operating income		36,410	52,064
Operating loss		(7,509)	(6,523)
		As at	As at
		June 30,	December 31,
		2020	2019
		(RMB'000)	(USD'000)
		(Unaudited)	(Unaudited)
Operating assets		2,274,908	2,117,352
Operating liabilities		960,485	855,843
Operating capital		1,314,423	1,261,509
Equity		1,186,459	1,164,484
Debt		127,964	97,025

...k... , ... C ... , ...
 ...
 ... A ...
 ... + ...
 ...
 ...
 ...

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review

... 22.8% ... B465.2 ... 2019. A ...
 ... 21.8% ... B438.9 ... 2019. D ...
 ... 26.3% (...
 ... 30, 2019: 22.3%). A ...
 ... B128.3 ... 39.4% ...
 ... 2019. D ...
 ... C ... B36.4 ... 2019, ...
 ... B26.2 ... 30.1% ...
 ... 2019, ...
 ... B13.3 ...
 ... F ... B4.8 ...
 ... k ... 2019 ...
 ... C ... 109.9%.

4.1.1 Revenue and Cost of Revenue

... : (-)
 ... ; (-) ... ; ... (-)
 ...
 ... k ... :

	For the six months ended June 30,	
	2020	2019
(RMB'000)	(B'000)	(B'000)
(Unaudited)	()	()
	438,886	360,210
	19,116	15,281
	7,148	3,419
Total revenue	465,150	378,910

the following table, the Company's revenue is broken down by type of service provided, and the revenue is broken down by type of service provided:

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Audited)
Inpatients		
Number of inpatient admissions	6,853	5,593
Revenue from inpatient admissions	1,240,393	1,012,333
Revenue from inpatient admissions as a percentage of total revenue	83.1	84.9
Revenue from inpatient admissions as a percentage of total revenue	1,030,392	859,061
Revenue from inpatient admissions as a percentage of total revenue (RMB'000)	324,990	251,945
Revenue from inpatient admissions as a percentage of total revenue (RMB)	315	293
Revenue from inpatient admissions as a percentage of total revenue (RMB'000)	53,841	50,926
Revenue from inpatient admissions as a percentage of total revenue (RMB)	52	59
Total inpatient revenue (RMB'000)	378,831	302,871
Total average inpatient spending per bed-day (RMB)	368	353
Outpatients		
Number of outpatient visits	125,852	105,986
Revenue from outpatient visits	12,761	11,635
Revenue from outpatient visits as a percentage of total revenue	101	110
Revenue from outpatient visits as a percentage of total revenue (RMB'000)	47,294	45,704
Revenue from outpatient visits as a percentage of total revenue (RMB)	376	431
Total outpatient revenue (RMB'000)	60,055	57,339
Total average outpatient spending per visit (RMB)	477	541
Total treatment and general healthcare services revenue (RMB'000)	337,751	263,580
Total pharmaceutical sales revenue (RMB'000)	101,135	96,630

Decreased 25.1% (2019: 19.9%); decreased 4.2% (2019: 86.3% (2019: 84.1%)).

Decreased 4.7% (2019: 18.7%); decreased 13.7% (2019: 15.9%).

Decreased 28.1% (2019: 77.0% (2019: 73.2%)); decreased 4.7% (2019: 23.0% (2019: 26.8%)); decreased 14.2% (2019: 30, 2019: 16.8%), decreased 78.8% (2019: 30, 2019: 79.7%).

Cost of revenue of owned hospitals

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (¥B'000) (Unaudited)
Cost of revenue of owned hospitals	112,156	101,813
Cost of revenue of leased hospitals	110,048	91,091
Cost of revenue of other hospitals	15,297	14,119
Cost of revenue of other hospitals	37,019	30,236
Cost of revenue of other hospitals	18,390	16,577
Cost of revenue of other hospitals	11,647	7,807
Cost of revenue of other hospitals	18,906	18,290
Cost of revenue of owned hospitals	323,463	279,933

D, 2019, 15.6%
 2019, 28.1%
 2019; ()
 ; ()

F 34.7% (30, 2019: 36.4%).
 34.0% (30, 2019: 32.5%).
 16.2% (30, 2019: 15.8%).

D
 B19.1
 B11.3 (30, 2019: B12.8);
 B5.8 (30, 2019:).

D
 B7.1 (30, 2019: B3.4
 B3.9 WE

4.1.2 Gross Profit and Gross Profit Margin

Year	Percentage	Change
2018	39.4%	▼B128.3
2019	43.8%	▼B115.4

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Audited)
Cost of sales	29.7%	25.1%
Depreciation and amortization	14.9%	14.5%
Interest expense	26.3%	22.3%
Income tax expense	47.1%	62.8%
Consolidated gross profit margin	27.6%	24.3%

Dr. ... 27.6% (... 30, 2019: 24.3%), ... 4.6 ... 2019, ...

4.1.3 Tax and Surcharge

Dr. _____, _____, 30, 2019: _____). B2.0

4.1.4 Selling Expenses

D. *Chrysomelidae* (30, 2019: 4.5%), *Curculionidae* (30, 2019: 3.7%), *Chrysomelidae* (30, 2019: 0.8%), *Curculionidae* (30, 2019: 1.2%).

4.1.5 Administrative Expenses

During the six months ended June 30, 2020, administrative expenses were RMB54.6 million, an increase of 3.3% from RMB52.9 million in 2019, an increase of 3.5% from RMB51.1 million in 2018. During the six months ended June 30, 2020, administrative expenses accounted for 12.4% (2019: 14.7%) of the net income.

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Employee salaries and benefits	35,136	33,962
Depreciation	5,970	5,709
Consulting fees	2,406	3,976
Other administrative expenses	1,468	2,188
	<u>9,659</u>	<u>7,055</u>
Total administrative expenses	<u>54,639</u>	<u>52,890</u>

During the six months ended June 30, 2020, administrative expenses were RMB54.6 million, an increase of 3.3% from RMB52.9 million in 2019, an increase of 3.5% from RMB51.1 million in 2018. During the six months ended June 30, 2020, administrative expenses accounted for 12.4% (2019: 14.7%) of the net income.

4.1.6 Research and Development Expenses

During the six months ended June 30, 2020, research and development expenses were RMB2.6 million, an increase of 14.5% from RMB2.3 million in 2019. During the six months ended June 30, 2020, research and development expenses accounted for 0.6% (2019: 0.6%) of the net income.

4.1.7 Finance Expenses – Net

For the six months ended June 30, 2020, the Company incurred net finance expenses of RMB4,921,000 (2019: RMB5,706,000). The net finance expenses for the six months ended June 30, 2020, consisted of:

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Interest income	2,454	1,925
Finance charges/(income)	125	(759)
Bank charges	(9,165)	(3,520)
Net finance expenses	(4,921)	(5,706)

Decreased by \$0.9 million, or 0.1%, from \$1.0 million in 2019. As a percentage of net sales, the provision for doubtful accounts was 0.1% in 2020 and 0.1% in 2019.

4.1.9 Credit Impairment Losses

During 2020, we recorded credit impairment losses of \$16.1 million, or 0.2% of net sales, compared to \$10.7 million, or 0.1%, in 2019, an increase of 3.5% (2019: 2.8%). As a percentage of net sales, credit impairment losses were 0.2% in 2020 and 0.1% in 2019. During 2020, we recorded credit impairment losses of \$30.3 million, or 0.3% of net sales, compared to \$21.4 million, or 0.2%, in 2019, an increase of 8.6% (2019: 7.1%).

4.1.10 Non-Operating Income (Expenses) and Other Gains

During 2020, we recorded non-operating income (expenses) and other gains of \$1.0 million, or 0.0% of net sales, compared to \$0.5 million, or 0.0%, in 2019, an increase of 0.0% (2019: 0.0%).

4.1.11 Income Tax Expense

[illegible]

4.2 Financial Position

4.2.1 Inventory

A, 30, 2020, $\Delta B_{33.9}$ (D
31, 2019: $\Delta B_{23.6}$), : (-
 $\Delta B_{31.3}$ (D 31, 2019: $\Delta B_{21.0}$);
(-) $\Delta B_{2.6}$ (D 31, 2019:
 $\Delta B_{2.6}$), 2701, 2806, 2807 2808
WE k B, C WE E, C
WE

C

2701, 2806, 2807
2808 WE k B,
C WE E,
C

[illegible]

...  ... 75%

$$(\mathbf{A} - \lambda \mathbf{I}) \begin{pmatrix} x \\ y \end{pmatrix} = \begin{pmatrix} 0 \\ 0 \end{pmatrix} \quad (19.3)$$
$$(\text{A}_{\text{max}} - \text{A}_{\text{min}}) (\text{min} - \text{max}) = 325.73$$
[illegible]

C *Chlamydomonas reinhardtii*

C. 2017, 30, 2017

4.2.2 Accounts Receivables

As at 30, 2020, Accounts Receivable was \$352.6 million (December 31, 2019: \$310.5 million), of which \$322.5 million, or 91.5%, was due from the top 10 customers. The average collection period was 14.5 days as at December 31, 2019, compared to 13.5 days as at December 31, 2019.

Details of Accounts Receivable by customer type are as follows:

Customer Type	December 31, 2020 (\$ million)	December 31, 2019 (\$ million)
Government	133	146

4.2.3 Other Receivables and Prepayments

As at 30, 2020, Other Receivables and Prepayments was \$88.4 million (December 31, 2019: \$68.7 million).

4.2.4 Investment Properties

As at 30, 2020, Investment Properties was \$107.1 million (December 31, 2019: \$110.9 million). Investment Properties includes the following:

Property	December 31, 2020 (\$ million)	December 31, 2019 (\$ million)
Bank of Canada Tower	302	303
Bank of Canada Tower (2/F to 11/F)	304	304

Details of Investment Properties by location are as follows:

Location	December 31, 2020 (\$ million)	December 31, 2019 (\$ million)
Bank of Canada Tower	302	303
Bank of Canada Tower (2/F to 11/F)	304	304

As at 30, 2020, Investment Properties was owned by the following entities:

Entity	Percentage	December 31, 2020 (\$ million)	December 31, 2019 (\$ million)
Bank of Canada	75%	1,959.41	6,766.36

The following table provides a summary of the carrying amounts of Investment Properties:

4.2.8 Contract Liability

A 30, 2020, B10.8 (D
31, 2019: B8.6).

4.2.9 Other Payables

A 30, 2020, $\Delta B93.5$ (D 31, 2019: $\Delta B133.3$).

4.3 Liquidity and Capital Resources

	For the six months ended June 30, 2020 (RMB'000) (Unaudited)	2019 (RMB'000) (Unaudited)
Cost of sales	17,799	4,157
Operating expenses	(76,436)	(75,880)
Operating income/(loss)	94,945	(25,941)
Finance income/(loss)	36,424	(98,423)

4.3.1 Net Cash Generated from Operating Activities

Figure 1 is a map of the study area, showing the location of the B17.8, B16.1, B28.9, B60.0, B90.9, WE, B14.5, and B17.8 stations. The map includes a coordinate grid and a scale bar.

4.3.2 Net Cash Used in Investing Activities

4.4.6 Exposure to Fluctuation in Exchange Rates

$\mathbf{k} \in \mathbb{R}^n$ is the wave vector, $\mathbf{D}$ is the diffusion tensor, $\mathbf{B}$ is the

F. ... 30, 2020, ... k.

C. ... k.

4.4.7 Gearing Ratio

A 30, 2020, 42.2% (D 31, 2019: 40.4%).

4.4.8 Employees and Remuneration Policy

A = 30, 2020: 3,136 ()
D = 31, 2019: 2,845 (). D = ,
()
B149.5 (30, 2019:
B128.1). B98.2
().

2018 WE C E
13, 2018 (2017 AGM-).
C 29, 2018 C
30, 2018.

A 2017 A-11, 8
B C A, 20, 2018,
165
1,818,529

A 15
 B C A 26, 2019,
 C B
 37
 273,161 A 14
 23
 180,516 0.2391%
 C
 (B10.47).

Category of personnel	Number of persons granted (<i>person</i>)	Number of Shares granted (<i>Share</i>)	Number of grant representing total issued share capital of the Company
C	17	142,311	0.1885%
B	6	38,204	0.0506%
	23	180,516	0.2391%

C
 WE
 (溫州箴言康寧投資管理合夥企業(有限合夥))
 k 48
 k 48

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

During the reporting period, the Company repurchased 899,700 shares of its ordinary shares at a total consideration of \$15,888,990. Details of the repurchases are as follows:

Repurchase period	Total number of H Shares repurchased	Price paid per share		Total consideration
		Highest (HK\$)	Lowest (HK\$)	
January 1 to December 31, 2020	35,000	17.90	17.80	624,200
January 1 to December 31, 2020	715,200	18.56	17.70	12,993,510
January 1 to December 31, 2020	9,400	16.00	15.80	148,540
January 1 to December 31, 2020	140,100	15.30	14.70	2,122,740
	899,700			15,888,990

The above table represents the total number of shares repurchased by the Company during the reporting period, 13, 2020.

The Company has not repurchased any shares of its ordinary shares during the reporting period, 13, 2020.

6 EVENTS AFTER THE REPORTING PERIOD

From January 1 to January 30, 2020, the Company has not repurchased any shares of its ordinary shares.

7 REVIEW OF INTERIM RESULTS

A, C 30, 2020,

A, C D, WE (A, C), D A

8 INTERIM DIVIDEND

B 30, 2020 (30, 2019:).

9 COMPLIANCE WITH CG CODE

C C-C

10 ACCOUNTING STANDARDS

C 2017, C A B, E C (C 622) (Companies Ordinance-).

11 FINANCIAL REPORT

11.1 Accounting Policies

A B, E B F C ("Ministry of Finance") F 15, 2006.

32 F A B, E F

2019. 2019

C 2016. C

11.2 Interim Financial Statement

For the six months ended June 30, 2020 and 2019, the consolidated income statement is as follows:

11.2.1 Interim Consolidated Income Statement

(Amounts in thousands of US dollars)

		For the six months ended June 30,	
		2020 (Unaudited)	2019 (Unaudited)
1. Revenue		465,150,452	378,910,291
Cost of sales		(336,864,754)	(286,882,183)
Gross profit		(1,999,246)	(831,972)
Operating expenses		(3,697,157)	(4,476,806)
Operating income		(54,639,015)	(52,890,346)
Finance income		(2,637,407)	(2,304,024)
Finance expense		(11,846,196)	(10,198,874)
Income before income taxes		(14,086,629)	(11,068,131)
Income taxes		2,454,371	1,925,426
Income before non-recurring items		5,443,616	6,567,461
Non-recurring items		(923,557)	23,549,073
Income from operations		(1,019,927)	(2,525,317)
Other income		(16,112,650)	(10,730,916)
Income from discontinued operations		—	(18,587)

11.2.2 Interim Consolidated Statement of Financial Position

(Amounts in thousands of US dollars)

ASSETS	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Current assets		
Cash and cash equivalents	216,156,858	176,030,550
Financial assets at fair value	–	30,000,000
Accounts receivable	352,645,140	310,520,612
Prepaid expenses and other receivables	76,843,282	63,317,366
Assets held for sale	11,516,259	5,366,020
Other current assets	33,858,107	23,568,236
Current assets held in connection with discontinued operations	–	12,688,704
Total current assets	691,019,646	621,491,488
Non-current assets		
Financial assets at fair value	51,281,869	51,281,869
Other non-current assets	94,068,266	89,943,193

LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Current liabilities		
Accounts payable	332,500,000	250,000,000
Accrued expenses	576,686	—
A. Short-term debt	63,565,539	75,554,960
C. Short-term debt	10,772,528	8,562,126
E. Short-term debt	23,923,352	36,063,277
Other short-term debt	44,736,621	33,430,060
Other current liabilities	93,516,092	133,348,712
C. Current portion of long-term debt	66,053,557	79,741,922
Total current liabilities	635,644,375	616,701,057
Non-current liabilities		
Long-term debt	100,500,000	20,000,000
Other non-current liabilities	186,013,332	183,808,151
Long-term debt	580,000	2,260,000
Other non-current liabilities	2,000,000	2,000,000
D. Long-term debt	9,797,371	9,949,267
D. Other non-current liabilities	25,949,596	21,124,118
Total non-current liabilities	324,840,299	239,141,536
Total liabilities	960,484,674	855,842,593
Shareholders' equity		
Common stock	75,500,000	75,500,000
Capital in excess of par value	826,376,743	824,715,445
Accumulated deficit	(37,817,508)	(21,721,144)
Accumulated other comprehensive income	33,189,321	33,189,321
Other equity	289,210,662	252,800,715
Total equity attributable to shareholders of the parent company	1,186,459,218	1,164,484,337
Equity attributable to non-controlling interests	127,964,021	97,024,925
Total shareholders' equity	1,314,423,239	1,261,509,262
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	2,274,907,913	2,117,351,855

11.2.3 Interim Consolidated Statements of Cash Flow

(A. ... B. ...)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Unaudited)
1. Cash flows from operating activities		
Cash received from customers	411,405,749	337,771,543
Cash received from other sources	8,311,056	7,188,089
Sub-total of cash inflows	419,716,805	344,959,632
Cash paid for operating expenses	(174,912,876)	(153,687,796)
Cash paid for interest and dividends	(162,022,960)	(137,201,128)
Cash paid for income taxes	(14,474,391)	(20,832,826)
Cash paid for other operating activities	(50,507,831)	(29,080,692)
Sub-total of cash outflows	(401,918,058)	(340,802,442)
Net cash flows from operating activities	17,798,747	4,157,190
2. Cash flows from investing activities		
Cash received from the sale of property, plant and equipment	30,010,000	447,095
Cash received from the sale of investments	96,370	—
Cash received from the sale of other assets	3,870,905	—
Cash paid for the acquisition of property, plant and equipment	—	1,833,758
Cash paid for the acquisition of investments	—	2,555,426
Sub-total of cash inflows	33,977,275	4,836,279
Cash paid for the acquisition of property, plant and equipment	(67,075,009)	(63,099,075)
Cash paid for the acquisition of investments	(15,145,000)	(13,020,000)
Cash paid for the acquisition of other assets	(25,593,510)	(1,246,349)
Cash paid for other investing activities	(2,600,000)	(3,351,048)
Sub-total of cash outflows	(110,413,519)	(80,716,472)
Net cash flows used in investing activities	(76,436,244)	(75,880,193)

		For the six months ended	
		June 30,	
		2020	2019
		(Unaudited)	(Unaudited)
3. Cash flows from financing activities			
Cash received from the issuance of bank loans		23,361,500	4,245,000
Cash received from the issuance of bank loans : Cash received from the issuance of bank loans			
Cash received from the issuance of bank loans		21,771,500	4,245,000
Cash received from the issuance of bank loans		367,285,789	170,000,000
Cash received from the issuance of bank loans		—	—
Sub-total of cash inflows		390,647,289	174,245,000
Cash paid for the acquisition of fixed assets		(201,900,000)	(146,000,000)
Cash paid for the acquisition of fixed assets		(8,241,036)	(6,647,896)
Cash paid for the acquisition of fixed assets		(85,561,157)	(47,538,263)
Sub-total of cash outflows		(295,702,193)	(200,186,159)
Net cash flows generated from/(used in) financing activities		94,945,096	(25,941,159)
4. Effect of foreign exchange rate changes on cash and cash equivalents		116,743	(758,597)
5. Net increase/(decrease) in cash and cash equivalents		36,424,342	(98,422,759)

[illegible]

	Equity attributable to shareholders of the parent company
Share capital	£737.0m
Reserves	£1,011.0m
	£1,748.0m

11.3 Notes to the Interim Financial Statement prepared in accordance with the China Accounting Standard for Business Enterprises

11.3.1 Accounts Receivable

(Amount in thousands of RMB)

	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Accounts receivable	6,750,000	8,250,000
Accounts receivable - related parties	384,779,056	330,174,215
Accounts receivable - non-related parties	391,529,056	338,424,215
Less: Allowance for doubtful accounts	(38,883,916)	(27,903,603)
Accounts receivable, net	352,645,140	310,520,612

The following table shows the aging of accounts receivable as of June 30, 2020 and December 31, 2019:

	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Within 1 year	307,256,118	266,932,953
1 to 2 years	54,328,309	57,988,407
2 to 3 years	24,130,088	13,089,001
Over 3 years	5,814,541	413,854
Total	391,529,056	338,424,215

Accounts receivable are measured at amortized cost less allowance for doubtful accounts.

11.3.2 Accounts Payable

(A.) (B.)

For the six months ended June 30, 2020 and June 30, 2019, the following amounts were due to suppliers:

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
W.E. 3	54,973,453	65,881,555
3. 6	5,224,098	7,479,995
6 1	2,277,029	1,381,101
1. 2	578,371	506,880
2. 3	276,874	94,816
3 3	235,714	210,613
	<u>63,565,539</u>	<u>75,554,960</u>

11.3.3 Revenue and Cost of Sales

(A.) (B.)

	For the six months ended June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Revenue	438,885,748	360,209,402
Cost of sales	<u>26,264,704</u>	<u>18,700,889</u>
	<u>465,150,452</u>	<u>378,910,291</u>
Cash	323,463,045	279,933,288
Cost of sales	<u>13,401,709</u>	<u>6,948,895</u>
	<u>336,864,754</u>	<u>286,882,183</u>

Revenue and cost of sales from main operations

(A. 2020/2019) (B. 2020/2019)

	For the six months ended June 30, 2020	
	(Unaudited) Revenue from main operations	(Unaudited) Cost of sales from main operations
Revenue from sales of goods	101,134,489	86,044,257
Revenue from services	337,751,259	237,418,788
	<u>438,885,748</u>	<u>323,463,045</u>
For the six months ended June 30, 2019		
	(Unaudited)	(Unaudited)
Revenue from sales of goods	96,629,883	82,628,810
Revenue from services	263,579,519	197,304,478
	<u>360,209,402</u>	<u>279,933,288</u>

11.3.4 Earnings Per Share

$$(A_1, \dots, A_n, B_1, \dots, B_m)$$

() B

	For the six months ended June 30, 2020 (Unaudited)	2019 (Audited)
Operating income	36,409,947	52,064,124
Other income	72,769,749	73,040,000
Basic earnings per share	0.50	0.71

(c) For the period from January 1, 2018, to December 31, 2020, the Company's net income was \$2,460,000. The Company's net income was \$2,460,000 for the period from January 1, 2018, to December 31, 2020. The Company's net income was \$2,460,000 for the period from January 1, 2018, to December 31, 2020.

F. 30, 2020, C. 899,700 k, C. 899,700 k.

() $D_{-1} \dots D_{-n}$

(1997, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 2680, 26

Dividends

12 DEFINITIONS

A, C	B
B, C	B, C, (北京怡寧醫院有限公司), A, 17, 2015, C
B	C
C, C	C, C, (蒼南康寧醫院有限公司), 15, 2012, C
C, C	C, C, (長春康林心理醫院有限公司), C, F, 16, 2016, C
C, WE	WE, C, k, C, k E, (k C : 2120)
C, C	C, C, A, 14
D, ()	() C
D, ()	() C, B1.00, B, k
WE	WE, C, (溫州怡寧老年醫院有限公司), 2, 2015, C
WE	C
()	() C, B1.00, B, k

1. 2012年12月12日，C. (永嘉康寧醫院有限公司)，
 D. 12, 2012, C.

%-

B. B.
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
 C.

2012年12月28日，C
 A. 28, 2020

A. C. D. A WE
 WE A WE A D. A WE
 WE A WE A D. A WE
 WE A WE A D. A WE